-
-
-
-
-
-
-
RBC Capital: 'Miebo remains the second-largest Rx DED drug in the US with 22.8% market share'
-
-
-
-
-
-
-
Bausch + Lomb Corporation (BLCO) Tops Q1 EPS by 3c, provides guidance
-
-
-
-
-
-
-
Bausch & Lomb Corp. (BLCO) PT Raised to $16 at Stifel, Hold Rating Maintained
-
-
-
-
-
-
-
Bausch + Lomb plans $2.8 billion loan refinancing to cut interest rates
-
-
-
-
-
-
-
Stifel Reiterates Hold Rating on Bausch & Lomb Corp. (BLCO); Says Cautious on New Market Execution
-
-
-
-
-
-
-
Bausch + Lomb Corporation (BLCO) Prices Upsized EUR 675M Notes Offering
-
-
-
-
-
-
-
Bausch + Lomb Corporation (BLCO) Misses Q1 EPS by 9c; raises guidance
-
445,862 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

